On Friday, Novavax ($NVAX@US) announced that they would be delaying their COVID-19 vaccine emergency authorization submission until their fourth quarter. Novavax is still poised to produce over 250 million doses of the vaccine by the end of the fourth quarter. Shares of Novavax are trading 18.85% lower at press time.
